US · ETON
Eton Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Deer Park, IL 60010-7208
- Website
- etonpharma.com
Price · as of 2024-12-31
$28.90
Market cap 455.63M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $61.66 | +113.36% |
| Intrinsic Value(DCF) | $864.33 | +2,890.76% |
| Graham-Dodd Method(GD) | $0.21 | -99.29% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $7.90 | ||||
| 2019 | $5.32 | ||||
| 2020 | $8.21 | $31.33 | $0.00 | $0.00 | $111.42 |
| 2021 | $3.94 | $8,578.96 | $0.30 | $0.31 | $0.00 |
| 2022 | $3.87 | $120.13 | $0.14 | $0.00 | $0.00 |
| 2023 | $4.50 | $32.63 | $145.97 | $0.42 | $0.00 |
| 2024 | $14.59 | $61.66 | $6.33 | $0.20 | $0.00 |
AI valuation
Our deep-learning model estimates Eton Pharmaceuticals, Inc.'s (ETON) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $61.66
- Current price
- $28.90
- AI upside
- +113.36%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$864.33
+2,890.76% upside
Graham-Dodd
$0.21
-99.29% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ETON | Eton Pharmaceuticals, Inc… | $28.90 | 455.63M | +113% | +2,891% | -99% | — | -98.83 | 15.47 | 9.68 | -270.70 | -31.78 | -36.14 | 60.01% | -6.66% | -9.80% | -19.16% | -13.35% | -7.09% | 1.22 | -1.30 | 2.06 | 1.02 | -10.33 | 31096.00% | 2329.00% | -8439.00% | 0.25% | 0.05 | 4.85% | 0.00% | 0.00% | 0.00% | -151.25 | 416.53 | 10.07 | 3.13 |
| ADCT | ADC Therapeutics S.A. | $4.10 | 507.9M | +465% | -82% | — | — | -1.13 | -0.88 | 2.52 | -0.50 | — | -0.88 | 91.60% | -184.44% | -222.83% | 89.97% | 41.28% | -46.65% | -0.61 | -2.60 | 3.82 | 3.37 | 1.25 | -4490.00% | 184.00% | 230.00% | -69.75% | -1.54 | 39.40% | 0.00% | 0.00% | 0.00% | -0.39 | -0.41 | 0.72 | -6.56 |
| BCYC | Bicycle Therapeutics plc | $5.73 | 397.02M | +373% | +110% | — | — | -3.52 | 0.75 | 16.88 | 1.67 | — | 0.75 | -390.34% | -594.96% | -479.18% | -29.04% | 217.72% | -21.78% | 0.01 | -121.31 | 13.81 | 13.61 | 5.28 | -4291.00% | 3076.00% | 16112.00% | -27.87% | -2.45 | 177.02% | 0.00% | 0.00% | 65.25% | 1.31 | 1.65 | -7.78 | 1.58 |
| FULC | Fulcrum Therapeutics, Inc… | $8.38 | 453.45M | +452% | — | — | — | -6.61 | 1.42 | — | -2.03 | -1.04 | 1.42 | 0.00% | — | — | -25.30% | -1230.41% | -23.89% | 0.02 | — | 27.40 | 27.00 | 2.60 | 63750.00% | -10000.00% | 231903.00% | -12.20% | -4.60 | -876.39% | 0.00% | 0.00% | 28.60% | -1.76 | -2.47 | — | 15.27 |
| LXRX | Lexicon Pharmaceuticals, … | $1.47 | 581.34M | +24,271% | +1,124% | — | — | -0.62 | 0.86 | 4.02 | 0.03 | — | 1.23 | 98.02% | -634.20% | -644.78% | -167.66% | -865.73% | -75.93% | 0.74 | -12.65 | 5.44 | 5.34 | -0.23 | -2125.00% | 248148.00% | 1074.00% | -144.07% | -3.95 | -789.72% | 0.00% | 0.00% | 34.92% | 0.02 | 0.03 | -0.15 | -10.01 |
| MNPR | Monopar Therapeutics Inc. | $54.81 | 366.24M | — | — | — | — | -20.88 | 5.91 | — | -16.41 | -15.53 | 5.91 | 0.00% | — | — | -51.42% | 471.62% | -46.09% | 0.00 | — | 11.47 | 11.46 | 2.83 | 13448.00% | — | -1850.00% | -1.97% | -1.22 | 186.88% | 0.00% | 0.00% | 11.85% | -16.41 | -41.42 | — | 35.62 |
| NMRA | Neumora Therapeutics, Inc… | $3.49 | 583.14M | — | — | — | — | -0.97 | 0.83 | — | 0.26 | -36.29 | 0.83 | 0.00% | — | — | -64.48% | -31666.35% | -59.96% | 0.01 | — | 10.51 | 10.29 | 0.53 | 268.00% | — | 1196.00% | -77.03% | -6.12 | -21987.50% | 0.00% | 0.00% | 0.00% | 0.26 | 0.37 | — | -1.09 |
| OCGN | Ocugen, Inc. | $1.82 | 595.72M | +1,481% | -87% | — | +155% | -3.06 | 5.58 | 40.77 | -2.64 | — | 5.58 | 51.47% | -1350.36% | -1333.02% | -154.01% | -938.91% | -73.55% | 1.10 | — | 2.86 | 2.71 | 0.49 | -2308.00% | -3282.00% | -3723.00% | -27.54% | -1.95 | -780.64% | 0.00% | 0.00% | 0.00% | -2.54 | -3.06 | 34.35 | -5.46 |
| OMER | Omeros Corporation | $12.05 | 854.35M | — | — | — | — | -2.84 | -2.44 | — | -3.58 | -6.51 | -2.44 | 0.00% | — | — | 151.08% | -341.82% | -47.86% | -1.13 | -6.86 | 1.69 | 1.60 | -1.30 | 4362.00% | — | -30050.00% | -33.43% | -1.87 | -300.85% | 0.00% | 0.00% | 36.52% | -3.32 | -3.78 | — | -5.80 |
| RAPT | RAPT Therapeutics, Inc. | $57.98 | 958.84M | — | — | — | — | -0.35 | 0.24 | — | 1.34 | -7.75 | 0.24 | 0.00% | — | — | -77.09% | 654.65% | -62.79% | 0.02 | — | 4.87 | 4.78 | 1.22 | 458.00% | — | -1503.00% | -181.11% | -1.72 | 401.25% | 0.00% | 0.00% | 270.67% | 1.33 | 2.16 | — | -3.97 |
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- CEO
- Sean E. Brynjelsen
- Employees
- 31
- Beta
- 1.22
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($864.33 ÷ $28.90) − 1 = +2,890.76% (DCF, example).